Vision Paper
VISION PAPER™ was created as a platform to bring together visionaries, scientists, physicians, entrepreneurs, investors and policymakers who believe that meaningful progress begins with meaningful dialogue.
A place to share ideas.
A place to build bridges across disciplines.
A place where knowledge can inspire action.
Not limited by profession.
Not limited by geography.
Not limited by conventional thinking.
The founding Manifesto and the first Vision Papers are currently in preparation.
This is only the beginning.
Where visionaries connect, ideas evolve, and the future takes shape.
VISION PAPER MANIFESTO
Veröffentlicht am 19. Juni 2026
Ideas that shape tomorrow
The greatest challenges of our time are not technological.
They are human.
Health.
Education.
Leadership.
Sustainability.
Artificial Intelligence.
Science.
Society.
We live in a world overflowing with information, yet increasingly lacking orientation.
Never before have we had access to so much knowledge, technology, expertise, and innovation.
Yet many of humanity’s most important challenges continue to grow.
The problem is not a lack of intelligence.
The problem is fragmentation.
We have experts everywhere.
But too few bridges between them.
VISION PAPER™ was created for those who do not merely wish to discuss the future, but are willing to help shape it.
We believe that meaningful progress emerges when different perspectives meet.
Where science meets experience.
Where technology meets ethics.
Where business meets responsibility.
Where vision meets action.
VISION PAPER™ is not a journal.
It is not a magazine.
It is a platform for ideas.
A platform for dialogue.
A platform for people who think beyond borders, disciplines, and systems.
Our community includes physicians.
Entrepreneurs.
Scientists.
Investors.
Artists.
Educators.
Policymakers.
Voices from East and West.
Emerging talents and experienced leaders.
Because the future does not belong to a single discipline.
It belongs to those who are willing to listen, learn from one another, and create new pathways together.
VISION PAPER™ is an invitation.
An invitation to think.
To connect.
To build.
To challenge assumptions.
To create solutions that no single discipline could achieve alone.
Because every meaningful transformation begins with an idea.
And every great idea begins with a vision.
The conversation starts now.
VISION PAPER™
Ideas that shape tomorrow.
VISION PAPER NR. 1
The Eye as a Gateway to Systemic Health
From Vision to Insight: Reframing Eye Health as a Catalyst for Healthy Longevity
Dr. Sylvia Paulig, MD
Founder & CEO, PAULIG EYE & HEALTH
Founder, PAULIG RESEARCH INSTITUTE
“I do not fear being overwhelmed. It tells me that the work I do truly matters.”
After more than three decades of surgical experience and scientific work, I no longer see vision correction as the ultimate goal of ophthalmology.
I see it as the starting point for something much deeper: a new framework for preventive medicine, healthy longevity, neurological insight, and human reconnection.
The future of healthcare will not be defined by how effectively we treat disease.
It will be defined by how early we recognize imbalance.
And few organs offer a clearer window into that process than the human eye.
The Eye: More Than an Organ of Vision
Traditionally, ophthalmology has focused on visual acuity, refractive correction, cataract surgery, glaucoma management, and retinal disease.
These remain essential pillars of modern eye care.
Yet the eye is far more than an isolated sensory organ.
Embryologically and anatomically, the retina and optic nerve are extensions of the central nervous system.
They belong to the brain.
As imaging technologies continue to advance, we are increasingly able to observe systemic processes through ocular structures long before symptoms emerge elsewhere in the body.
The eye therefore represents not only a visual organ but also a diagnostic interface between neurology, vascular biology, metabolism, aging, and overall health.
Ocular Biomarkers of Aging and Systemic Dysfunction
At PAULIG EYE & HEALTH, we have integrated advanced retinal imaging and systemic diagnostics into daily clinical practice.
This approach has revealed how frequently changes within the eye mirror broader physiological processes.
Among the most relevant observations are:
* Retinal Nerve Fibre Layer (RNFL) thinning as an early indicator of neurodegeneration, including glaucoma, cognitive decline, Alzheimer’s disease, and other neurological disorders.
* Alterations in optic nerve head perfusion and retinal microvasculature, which may reflect vascular aging, endothelial dysfunction, and mitochondrial stress.
* Choroidal thinning and abnormalities detected through OCT-Angiography, often associated with chronic inflammation and impaired systemic regulation.
* Elevated homocysteine levels, linked not only to cardiovascular disease but also to glaucoma progression, cognitive decline, and accelerated biological aging.
These findings suggest that the eye may serve as one of the most accessible and non-invasive platforms for monitoring human aging in real time.
The implications extend far beyond ophthalmology.
From Disease Detection to Preventive Stratification
The next evolution of medicine requires a shift from reactive treatment toward proactive prevention.
The eye offers a unique opportunity to support this transition.
By combining ocular biomarkers with systemic assessments, patients can be guided into individualized preventive pathways that may include:
* Nutritional optimization, including Vitamin B12, folate, Omega-3 fatty acids, and micronutrient support.
* Mitochondrial and metabolic interventions designed to improve cellular resilience and energy production.
* Lifestyle and exercise strategies that influence biological aging and neurovascular health.
* Stress assessment and psycho-emotional evaluation when chronic dysregulation is suspected.
* Education regarding epigenetics, behavioral patterns, and long-term health responsibility.
In this framework, ophthalmology evolves beyond vision correction.
It becomes an early-warning system for systemic health.
Bridging Disciplines, Cultures, and Systems
My work has never been driven solely by technology or surgical precision.
It has been guided by a deeper question:
How can we understand health more completely?
This question naturally leads beyond the boundaries of traditional medical disciplines.
It requires dialogue between neuroscience, preventive medicine, longevity science, psychology, nutrition, systems biology, and public health.
It also requires openness toward integrative approaches that seek to understand the individual as a whole.
The future of healthcare will be built through bridges:
* Between clinical medicine and public health.
* Between prevention and treatment.
* Between Western scientific precision and Eastern traditions of healing.
* Between physicians and patients.
* Between science and humanity.
* Between continents, cultures, and systems of knowledge.
As a Board Member of GHORFA and through international collaborations across Europe and the Arab world, I have witnessed the value of knowledge exchange that transcends geographical and disciplinary boundaries.
Innovation emerges where perspectives meet.
Vision Beyond the Eye
To see clearly is not only a physiological act.
It is also a metaphor.
Vision represents insight, direction, awareness, and responsibility.
If we seek to build a future of sustainable and dignified longevity, we must learn to see beyond symptoms and recognize the human being in full context — biologically, emotionally, socially, and culturally.
Healthy longevity begins with clarity.
Clarity in the eye.
Clarity in the body.
Clarity in the mind.
Through ocular biomarkers, we gain access to neurological and metabolic processes that shape the aging trajectory.
Through interdisciplinary dialogue, we create systems that prioritize prevention rather than reaction.
Through a broader understanding of vision, we begin not only to detect disease earlier but also to recognize imbalance before disease develops.
That may become one of the most important tasks of medicine in the twenty-first century.
Conclusion
The eye is more than a window to the soul.
It is a gateway to systemic health.
By integrating advanced diagnostics, longevity science, preventive medicine, and human-centered care, ophthalmology can become one of the leading disciplines in the transformation from disease management to health optimization.
The future of medicine will belong to those willing to see connections where others see boundaries.
And every meaningful transformation begins with vision.
⸻
The Eye as a Gateway to Systemic Health
This publication marks the beginning of the VISION PAPER™ initiative — a platform dedicated to bridging medicine, science, technology, leadership, longevity, and human development.
The future belongs not to isolated disciplines, but to meaningful connections between them.
More Vision Papers will follow.
VISION PAPER NO. 2
Why Scientific Publishing Needs Vision Papers
Why Science Needs New Formats for Thinking
Ideas Shape the Future Before Data Confirms It
For centuries, scientific journals have played an indispensable role in human progress.
They transformed observations into evidence.
Evidence into knowledge.
Knowledge into innovation.
Modern medicine, technology, and science would not exist without the rigorous structures that scientific publishing has created.
Yet every successful system eventually reaches a point where evolution becomes necessary.
Scientific publishing is no exception.
Today, humanity faces challenges that no longer belong to a single discipline.
Healthcare.
Longevity.
Artificial Intelligence.
Climate Change.
Mental Health.
Education.
Leadership.
Sustainability.
These challenges are interconnected.
Yet our systems for creating and sharing knowledge remain largely fragmented.
Researchers are encouraged to specialize.
Institutions are organized around disciplines.
Journals are categorized into increasingly narrow fields of expertise.
This structure has produced remarkable scientific advances.
But it has also created an unintended consequence:
We have become exceptionally good at generating knowledge.
We are far less effective at connecting it.
Every Breakthrough Begins With an Idea
History reminds us that transformative discoveries rarely begin with data alone.
They begin with questions.
With observations.
With curiosity.
With the willingness to imagine possibilities before they can be measured.
Albert Einstein developed concepts that experiments would confirm years later.
Rudolf Virchow transformed medicine by challenging prevailing assumptions about disease.
Countless scientific breakthroughs emerged because someone was willing to think beyond existing frameworks.
Evidence is essential.
But evidence does not appear spontaneously.
Before every discovery comes an idea.
Before every experiment comes a hypothesis.
Before every breakthrough comes a vision.
Yet modern scientific publishing often provides little space for ideas that are still emerging.
There is limited room for interdisciplinary perspectives.
Limited room for conceptual thinking.
Limited room for informed hypotheses that connect multiple domains of expertise.
Limited room for vision.
The Missing Space Between Knowledge and Innovation
Traditional scientific journals serve a critical purpose.
They validate.
They verify.
They protect scientific integrity.
And they should continue to do so.
Vision Papers are not intended to replace scientific publications.
Nor are they designed to bypass scientific rigor.
Instead, they serve a different function.
They create a space where new ideas can be explored before sufficient evidence exists to support them fully.
A space where experts from different fields can connect perspectives.
A space where medicine can learn from technology.
Where science can learn from philosophy.
Where healthcare can learn from leadership.
Where innovation can emerge through dialogue rather than specialization alone.
Vision Papers are not about certainty.
They are about possibility.
From Gatekeeping to Global Dialogue
Scientific journals remain essential for validating evidence.
Their role should not be replaced.
However, the path from an idea to publication can be long, complex, and highly selective.
Editors make decisions.
Reviewers evaluate manuscripts.
Publication cycles may take months or even years.
These processes are necessary for scientific quality.
Yet they can also slow the exchange of emerging ideas.
Many concepts that deserve discussion never reach a broader audience.
Not because they are wrong.
But because they are early.
Interdisciplinary.
Difficult to categorize.
Or simply ahead of their time.
VISION PAPER™ was created to provide an additional pathway.
A space where ideas can be shared, challenged, refined, and discussed internationally before they become fully established scientific knowledge.
A Vision Paper is not a final conclusion.
It is the beginning of a conversation.
Its purpose is not to declare truth.
Its purpose is to invite dialogue.
By making ideas accessible earlier, connections can emerge faster.
Researchers can discover collaborators.
Entrepreneurs can identify opportunities.
Policymakers can recognize future challenges.
Investors can better understand emerging directions.
Most importantly, knowledge can move more freely across disciplines, industries, and borders.
In a rapidly changing world, the speed of meaningful dialogue may become as important as the speed of innovation itself.
Why Vision Matters Now
We live in an era defined by exponential change.
Artificial intelligence is transforming industries.
Healthcare systems are struggling under the burden of chronic disease.
Longevity science is challenging traditional concepts of aging.
Technology evolves faster than regulation.
Information grows faster than understanding.
The world does not need more information alone.
It needs better integration of knowledge.
It needs bridges.
Between disciplines.
Between generations.
Between cultures.
Between science and society.
The greatest opportunities of the future will emerge at these intersections.
Yet these intersections are often where traditional publishing is least comfortable.
Vision Papers were created to explore precisely these spaces.
Building Bridges for the Future
The purpose of a Vision Paper is simple.
To connect ideas.
To encourage dialogue.
To stimulate collaboration.
To explore possibilities.
To inspire action.
A Vision Paper is not a final answer.
It is an invitation.
An invitation to think differently.
To ask new questions.
To challenge assumptions.
To connect knowledge that may otherwise remain separated.
Science advances through evidence.
But it also advances through imagination.
The future will belong not only to those who generate knowledge.
It will belong to those who connect it.
Scientific journals provide the evidence.
Vision Papers provide the space where tomorrow’s evidence may first begin.
Both are necessary.
Both are valuable.
And together, they may help shape a future that no discipline could create alone.
VISION PAPER NO.3
VISION PAPER™ No. 3
Health Is Not Created in Hospitals
The Missing Link Between Nature, Movement, Light and Human Regeneration
By Dr. Sylvia Paulig
⸻
Introduction
Modern medicine has achieved extraordinary success.
We can replace joints, implant artificial lenses, perform complex surgeries, sequence genomes, and increasingly use artificial intelligence to support diagnosis and treatment.
Yet despite these advances, chronic diseases continue to rise worldwide.
Healthcare expenditures are increasing.
Mental health challenges are growing.
Obesity, diabetes, cardiovascular disease, myopia, sleep disorders, and neurodegenerative conditions are affecting people at younger ages than ever before.
The question is no longer whether we can treat disease.
The question is why we are creating so much disease in the first place.
Perhaps one of the greatest misunderstandings of modern healthcare is the belief that health is created in hospitals.
It is not.
Hospitals are essential when disease occurs.
But health itself is created long before a patient enters a clinic.
⸻
- The Great Misunderstanding
Healthcare systems around the world are largely designed to diagnose and treat disease.
This is necessary.
However, treating disease and creating health are not the same thing.
Most chronic illnesses develop over years or decades before a diagnosis is made.
The true challenge of the future is not only how to treat disease more effectively.
It is how to create health before disease begins.
For decades, success in healthcare has often been measured by the ability to intervene after dysfunction has already occurred.
The next evolution of healthcare may require a different perspective.
One that focuses not only on disease management, but on health creation.
⸻
- Health Is Created Every Day
Health is not a product of occasional medical interventions.
It is the result of countless biological processes occurring every day.
Health is created through movement.
Through natural light.
Through restorative sleep.
Through nutrition.
Through emotional resilience.
Through meaningful human relationships.
Through purpose.
Through the interaction between human biology and the environment.
Every cell continuously responds to signals from the outside world.
These signals influence metabolism, hormonal balance, immune function, inflammation, mitochondrial performance, and regeneration.
The body is not a machine waiting to be repaired.
It is a living system continuously adapting to its environment.
⸻
- The Forgotten Biology of Human Health
For most of human history, humans lived in close alignment with natural biological rhythms.
We moved throughout the day.
We were exposed to natural daylight.
We experienced darkness at night.
We maintained strong social bonds within communities.
Our biology evolved under these conditions.
Modern life has changed them dramatically.
Many people spend most of their day indoors.
Physical activity has declined.
Artificial light extends waking hours.
Digital devices compete for attention.
Stress has become chronic.
Recovery has become optional.
The consequences are visible everywhere.
The growing burden of chronic disease may not simply reflect medical challenges.
It may reflect a growing disconnect between human biology and modern lifestyles.
⸻
- Why Chronic Disease Is Exploding
Despite unprecedented medical innovation, chronic diseases continue to increase globally.
Obesity.
Type 2 diabetes.
Cardiovascular disease.
Autoimmune disorders.
Burnout.
Depression.
Myopia.
Neurodegenerative diseases.
These conditions are often approached as separate medical entities.
Yet many share common underlying drivers.
Chronic inflammation.
Metabolic dysfunction.
Circadian disruption.
Physical inactivity.
Psychological stress.
Loss of social connection.
When the body’s self-regulatory systems are continuously challenged, disease becomes more likely.
The challenge facing healthcare systems is therefore not only how to treat these conditions.
It is how to prevent the biological imbalance that precedes them.
⸻
- The Eye as an Early Window into Systemic Health
The eye offers a unique opportunity to observe human health in real time.
Changes in retinal blood vessels may reflect cardiovascular risk.
Retinal nerve fiber alterations may reveal neurodegenerative processes.
Myopia reflects environmental and behavioral influences affecting millions of children worldwide.
Sleep disturbances influence ocular health.
Inflammation influences ocular health.
Metabolic dysfunction influences ocular health.
The eye does not exist separately from the rest of the body.
It reflects systemic health.
In many cases, it may reveal biological stress long before symptoms become apparent elsewhere.
This is why prevention and early detection must become central pillars of future medicine.
⸻
- From Repair Medicine to Regulation Medicine
Medicine will always require expertise in treating disease.
However, the future may demand more than repair.
It may require a shift toward regulation.
Supporting the body’s capacity for adaptation.
Strengthening resilience.
Identifying imbalance before dysfunction becomes irreversible.
Technology will play an important role.
Biomarkers.
Artificial intelligence.
Digital monitoring.
Precision diagnostics.
Advanced imaging.
But technology alone is not enough.
The future of healthcare requires a deeper understanding of how health is created in the first place.
The goal is not merely to extend lifespan.
The goal is to improve healthspan.
⸻
- A New Vision for Healthcare
Future healthcare systems must integrate treatment and prevention.
Science and human behavior.
Technology and biology.
Innovation and responsibility.
The healthcare systems of tomorrow should reward health creation, not only disease treatment.
They should encourage movement.
Support healthy environments.
Promote early detection.
Strengthen individual responsibility.
Empower patients.
Preserve human connection.
The goal should not simply be to help people survive longer.
The goal should be to help people remain healthy, functional, independent, and resilient throughout life.
This requires a broader definition of medicine.
One that recognizes a simple truth:
Hospitals treat disease.
But daily life creates health.
⸻
Conclusion
The future of healthcare is not only about developing better treatments.
It is about understanding the conditions under which human health can thrive.
Health is not created in hospitals.
Health is created in everyday life.
The future of healthcare will belong to those who learn how to protect and strengthen human self-regulation before disease begins.
Because prevention is not a medical specialty.
Prevention is the foundation upon which sustainable healthcare systems must be built.
VISION PAPER NO.4
Back to the Basics
Rediscovering the Biological Foundations of Medicine
Why the Future of Medicine Begins with Cell Biology, Biochemistry and General Pathology
A Call for Scientific Humility Before Nature
Medicine has become increasingly specialized.
Biology has not.
⸻
Abstract
Medicine has never possessed more knowledge, more technology or more precision than today.
Artificial intelligence, molecular diagnostics, precision medicine and regenerative therapies are transforming healthcare at an unprecedented pace. These achievements have profoundly improved diagnosis, treatment and patient outcomes across virtually every medical discipline.
Yet despite these remarkable scientific advances, chronic diseases continue to increase worldwide. Healthcare systems remain predominantly focused on managing established pathology, while prevention frequently begins only after structural disease has already developed.
Perhaps the challenge is not a lack of scientific knowledge.
Perhaps it is fragmentation.
Modern medicine has become increasingly specialized. Biology has not.
Every living cell—whether located in the retina, brain, heart, kidney or liver—depends upon the same fundamental biological principles. Energy production, oxygen utilization, cellular communication, adaptation, repair and homeostasis are not organ-specific concepts. They represent the universal biological language that sustains life itself.
This Vision Paper proposes that future progress in medicine will depend not only on deeper specialization but also on rediscovering the biological foundations shared by every medical discipline. Returning to the principles of cell biology, biochemistry and general pathology is therefore not a step backwards. It is a necessary step towards a more integrated, preventive and biologically coherent understanding of health.
Scientific innovation and biological understanding should not compete.
They should evolve together.
⸻
- Life Has No Specialties
Life is extraordinarily complex.
Yet it is governed by remarkably simple biological principles.
Every human being begins as a single cell. From this single cell develops an organism composed of trillions of cells, hundreds of specialized cell types and numerous highly differentiated organs. Their structures differ profoundly. Their biological foundations do not.
Medicine has always sought to understand this complexity.
As scientific knowledge expanded, specialization became inevitable. Dividing medicine into disciplines enabled physicians and scientists to study organs, diseases and therapeutic strategies with unprecedented depth. Ophthalmology, cardiology, neurology, nephrology, endocrinology and countless other specialties have transformed healthcare and continue to improve the lives of millions of people.
Specialization is therefore not a weakness of medicine.
It is one of its greatest achievements.
Yet biology follows another logic.
Nature never divided the human body into specialties.
Every organ communicates continuously with every other organ. Hormones circulate throughout the body. Immune cells migrate between tissues. Neural networks integrate sensory information with autonomic regulation. Metabolism links every cell through a common biochemical framework.
Life functions as one integrated system.
A retinal neuron and a cortical neuron perform different functions, yet both depend upon mitochondrial energy production, intracellular communication, protein homeostasis and adaptive regulation. Cardiomyocytes, hepatocytes and renal tubular cells differ anatomically, but the biological principles governing their survival remain remarkably similar.
The organ changes.
The biological language does not.
Recognizing this distinction does not diminish specialization.
It strengthens it.
Because every specialty ultimately investigates a different expression of the same biological phenomenon:
Life
- Every Cell Speaks the Same Biological Language
Every living organism begins with a single cell.
From this single cell emerges one of the most sophisticated biological systems known to science. Trillions of cells differentiate into highly specialized tissues and organs, each performing distinct physiological functions. Yet despite this remarkable diversity, every living cell continues to obey the same fundamental biological principles.
This observation may appear self-evident.
Its implications for medicine are profound.
For more than a century, cell biology, biochemistry and general pathology have provided the scientific foundation upon which every clinical discipline is built. Regardless of anatomical location, every cell requires energy, oxygen, nutrients and precisely regulated communication with its environment. Every cell must maintain intracellular homeostasis, respond to physiological stress, repair molecular damage and continuously adapt to changing conditions.
These mechanisms are not specific to one organ.
They define life itself.
Health begins at the cellular level long before it becomes visible at the level of organs.
Every second, billions of cells respond to fluctuations in oxygen availability, nutrient supply, hormones, inflammatory mediators, mechanical forces and environmental influences. Their ability to adapt determines whether physiological function can be preserved despite continuous biological challenges.
Homeostasis should therefore not be understood as a static condition.
It is a dynamic process of continuous regulation.
This distinction is fundamental.
Living systems do not remain healthy because nothing changes.
They remain healthy because they continuously adapt to change.
General pathology traditionally distinguishes between adaptation, reversible cellular injury and irreversible cellular injury. Although these concepts were established many decades ago, they remain among the most important principles in medicine because they describe an universal biological sequence rather than an organ-specific disease.
Long before structural pathology becomes clinically apparent, cells may already experience declining mitochondrial efficiency, impaired intracellular communication, disturbed protein homeostasis, oxidative stress or reduced repair capacity. During this phase, compensatory mechanisms often preserve normal physiological function, making these early biological alterations largely invisible in routine clinical practice.
Only when compensation gradually fails do functional disturbances become clinically detectable.
Structural damage frequently represents the final stage of biological processes that have evolved silently over many years.
From a biological perspective, disease rarely begins at the moment it becomes visible.
It begins much earlier.
Perhaps the earliest manifestations of disease are not structural at all.
Perhaps they represent the first subtle decline in the extraordinary ability of living cells to regulate themselves.
This perspective does not replace disease-specific diagnostics.
It expands them.
Instead of asking only where disease appears, it encourages us to ask how biological regulation gradually becomes impaired.
This shift in perspective may become one of the defining characteristics of future preventive medicine.
- Health Is the Ability to Regulate
Health has traditionally been described as the absence of disease.
Although this definition has served medicine well, it explains health primarily by what is missing rather than by what is present.
Biology offers another perspective.
Living organisms are not healthy simply because no diagnosis has yet been established.
They are healthy because they continuously regulate themselves.
Every moment of life depends upon regulation.
Body temperature is regulated.
Blood pressure is regulated.
Blood glucose is regulated.
Electrolyte balance is regulated.
Hormonal activity is regulated.
Immune responses are regulated.
Sleep and circadian rhythms are regulated.
Cellular repair is regulated.
Even adaptation itself is regulated.
Health is therefore not a static condition.
It is a dynamic biological process.
Every second, billions of cells sense changes in their internal and external environment. They exchange information, adjust metabolic pathways, repair molecular damage and respond to new physiological demands. These processes occur continuously and almost entirely without conscious awareness.
Together, they create what we experience as health.
One of the most remarkable characteristics of living systems is their capacity to compensate.
When biological stress increases, protective mechanisms are activated. Cellular metabolism adjusts to changing energy demands. Hormonal networks stabilize the internal environment. The immune system responds to injury and infection. Damaged tissues initiate repair, while neighboring cells help preserve function.
For prolonged periods, these adaptive mechanisms successfully maintain physiological stability despite increasing biological challenges.
Health should therefore not be understood as the absence of stress or the absence of change.
On the contrary.
Life depends upon constant change.
Health is the ability to respond to that change while preserving biological function.
Eventually, however, adaptive capacity may begin to decline.
Compensation becomes less efficient.
Maintaining equilibrium requires increasing biological effort.
Functional disturbances begin to emerge.
Only later do structural abnormalities become clinically apparent.
Seen from this perspective, structural pathology is often not the beginning of disease.
It is the visible consequence of biological processes that have been developing over months or even years.
This distinction changes the way we think about prevention.
If health is fundamentally the preservation of biological regulation, then preventive medicine should not focus exclusively on detecting established disease. It should also strive to recognize the earliest signs that biological regulation is becoming less resilient.
This approach does not replace conventional diagnostics.
It complements them.
Rather than waiting until structure has changed, it encourages us to understand the biological processes that precede structural damage.
Health, therefore, is not defined by perfection.
Living systems are never perfect.
They constantly adapt, compensate and recover.
Health is the ability to maintain this remarkable dynamic balance throughout life.
Perhaps this is one of the most important lessons biology teaches us.
The opposite of health is not disease.
From a biological perspective, disease may often be understood as the progressive loss of the ability to regulate.
- The Human Body Functions as One Integrated Biological System
The human body is often described organ by organ.
Biology functions differently.
No organ exists independently.
The heart cannot function without the lungs.
The brain depends upon continuous energy delivery through the cardiovascular system.
The kidneys maintain the internal environment required for every cell to survive.
The liver regulates metabolism throughout the organism.
The endocrine system coordinates physiological adaptation.
The immune system communicates continuously with virtually every tissue.
Even the extracellular matrix, once regarded primarily as structural support, actively participates in cellular signaling, tissue organization and biological regulation.
Life is sustained through interaction.
Not through independence.
Every physiological system influences countless others.
Every biological process forms part of a larger network.
The remarkable complexity of the human body therefore does not arise because organs function separately.
It arises because they function together.
This distinction becomes increasingly important as medicine continues to advance.
Scientific specialization allows us to understand organs in extraordinary detail.
Systems biology reminds us that no organ can be understood completely without considering the organism to which it belongs.
Depth and integration are therefore not competing concepts.
They are complementary.
The future of medicine requires both.
Understanding the molecular mechanisms of disease will remain essential.
Understanding how these mechanisms interact across the organism may become equally important.
This perspective also changes the way we think about prevention.
Traditionally, medicine identifies disease once structural abnormalities become detectable within a particular organ.
An integrated biological perspective encourages an additional question.
What changes occurred before structure changed?
What happened while cells were still adapting?
What biological signals reflected the gradual decline in physiological resilience?
These questions move prevention closer to the biology of health rather than solely to the pathology of disease.
They do not replace established diagnostic pathways.
They broaden them.
Within this biological framework, every organ reflects the same universal principles of cellular life.
Some organs, however, allow these principles to be observed more directly than others.
The eye is one such organ.
Unlike most tissues, the retina and optic nerve can be examined repeatedly, non-invasively and with remarkable structural resolution throughout life.
Retinal neurons depend upon uninterrupted energy production.
Their function is influenced by oxygen availability, vascular regulation, metabolism, inflammation and aging.
In this respect, the eye is not biologically unique.
It follows the same universal principles that govern every other organ.
Its uniqueness lies elsewhere.
It offers a rare opportunity to observe living neural and microvascular tissue directly.
For this reason, the eye should not be regarded merely as an organ of vision.
It represents a clinically accessible example of integrated human biology.
Not because it follows different biological rules.
But because it allows us to observe the same biological rules more directly than many other organs.
Perhaps this is its greatest contribution to future medicine.
Not to stand apart from biology—
but to remind us that it has always been part of it.
- Back to the Basics
Every generation of physicians has benefited from the scientific discoveries of those who came before them.
Anatomy provided structure.
Physiology explained function.
Biochemistry revealed molecular interactions.
Cell biology uncovered the fundamental mechanisms of life.
General pathology demonstrated how health gradually gives way to disease.
Modern medicine has expanded this knowledge through molecular genetics, advanced imaging, precision medicine, regenerative therapies and artificial intelligence.
Each of these achievements represents extraordinary scientific progress.
None of them replaces the biological principles upon which they are built.
Technology continues to evolve.
Biology remains.
Every biomarker derives its meaning from physiology.
Every diagnostic image reflects underlying cellular processes.
Every therapeutic intervention ultimately seeks to preserve or restore biological function.
No technological innovation can be fully understood without understanding the biology it measures, influences or attempts to repair.
For this reason, returning to the biological foundations of medicine is not a nostalgic view of the past.
It is an investment in the future.
Scientific progress should not lead us away from first principles.
It should deepen our understanding of them.
The future of medicine will undoubtedly become increasingly digital, increasingly precise and increasingly individualized.
At the same time, it should remain firmly connected to the universal biological principles shared by every living cell.
Scientific humility therefore becomes an essential companion to scientific innovation.
The more deeply we explore biology, the more clearly we recognize the extraordinary complexity of life and the remarkable elegance of its underlying principles.
Humility does not limit scientific ambition.
It strengthens it.
It reminds us that discovery begins with observation, that innovation grows from understanding and that every technological advance remains meaningful only when grounded in biological reality.
Perhaps the next great step in medicine will not arise solely from discovering entirely new mechanisms.
Perhaps it will also arise from recognizing the biological connections that have always existed but have gradually become obscured by increasing specialization.
Medicine has become increasingly specialized.
Biology has not.
The future of medicine will therefore depend not only upon how deeply we understand individual disciplines, but also upon how clearly we understand the biological principles they all share.
Because every specialty ultimately studies the same phenomenon.
Life.
⸻
Final Reflection
For centuries, medicine has advanced by looking deeper.
We explored organs.
Then tissues.
Then cells.
Then molecules.
Then genes.
Today, we can observe biology with a level of precision that previous generations could scarcely imagine.
Yet one fundamental truth has remained unchanged.
Life has always functioned as an integrated biological system.
Every cell.
Every tissue.
Every organ.
Every physiological process.
Connected.
Perhaps the next chapter of medicine will not begin by dividing biology even further.
Perhaps it will begin by reconnecting it.
Not by abandoning specialization.
But by complementing it with a deeper understanding of the biological foundations shared by every discipline.
Scientific progress and biological understanding should evolve together.
One drives innovation.
The other provides direction.
The future of medicine will not be built by leaving biology behind.
It will be built by understanding it more deeply than ever before.
Conceptual Note
This Vision Paper presents a conceptual perspective intended to stimulate interdisciplinary scientific discussion. It does not propose a new disease model, redefine established pathology or replace evidence-based clinical practice. Instead, it highlights universal biological principles that may support future preventive, integrative and systems-oriented approaches to medicine.
References1. Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 7th ed. Garland Science; 2022. 2. Kumar V, Abbas AK, Aster JC. Robbins & Cotran Pathologic Basis of Disease. 11th ed. Elsevier; 2020. 3. Hall JE. Guyton and Hall Textbook of Medical Physiology. 15th ed. Elsevier; 2023. 4. Lodish H, Berk A, Kaiser CA, et al. Molecular Cell Biology. 9th ed. W.H. Freeman; 2021. 5. Berg JM, Tymoczko JL, Gatto GJ, Stryer L. Biochemistry. 9th ed. W.H. Freeman; 2019. 6. Nelson DL, Cox MM. Lehninger Principles of Biochemistry. 8th ed. W.H. Freeman; 2021. 7. Cannon WB. The Wisdom of the Body. W.W. Norton & Company; 1932. 8. Selye H. The Stress of Life. McGraw-Hill; 1956. 9. Kitano H. Systems biology: A brief overview. Science. 2002;295:1662–1664. 10. Kitano H. Biological robustness. Nature Reviews Genetics. 2004;5:826–837. 11. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The Hallmarks of Aging. Cell. 2013;153:1194–1217. 12. López-Otín C, Blasco MA, Partridge L, et al. Hallmarks of Aging: An Expanding Universe. Cell. 2023;186:243–278. 13. Kennedy BK, Berger SL, Brunet A, et al. Geroscience: Linking Aging to Chronic Disease. Cell. 2014;159:709–713. 14. Kotas ME, Medzhitov R. Homeostasis, Inflammation, and Disease Susceptibility. Cell. 2015;160:816–827. 15. Sterling P, Eyer J. Allostasis: A New Paradigm to Explain Arousal Pathology. In: Handbook of Life Stress, Cognition and Health. Wiley; 1988. 16. Friston K. The Free-Energy Principle: A Unified Brain Theory? Nature Reviews Neuroscience. 2010;11:127–138. 17. Hood L, Friend SH. Predictive, Preventive, Personalized and Participatory (P4) Medicine. Nature Reviews Clinical Oncology. 2011;8:184–187. 18. Topol EJ. Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. Basic Books; 2019. 19. World Health Organization. Constitution of the World Health Organization. Geneva: WHO; 1948. 20. National Academies of Sciences, Engineering, and Medicine. Systems Approaches to Improve Patient Care. National Academies Press.
VISION PAPER NO.5
Beyond Intraocular Pressure
Rethinking Normal-Tension Glaucoma Through Biomechanics, Cellular Resilience and Neuroprotection
5.1 When Pressure Is Not Enough
For decades, glaucoma has been regarded primarily as a pressure-related disease. Elevated intraocular pressure (IOP) remains the most important modifiable risk factor, and lowering IOP is currently the only treatment strategy consistently proven to slow disease progression. This paradigm has transformed ophthalmic care and preserved the vision of millions of patients worldwide.
Nevertheless, one fundamental question remains unanswered.
Why do retinal ganglion cells continue to degenerate in many patients whose intraocular pressure has always remained within the statistically normal range?
Normal-tension glaucoma (NTG) represents one of the most compelling challenges to the traditional pressure-centered concept of glaucoma. Particularly in East Asian populations, NTG accounts for a substantial proportion of primary open-angle glaucoma, suggesting that elevated IOP alone cannot fully explain the mechanisms underlying progressive optic nerve damage.
Rather than viewing NTG simply as “glaucoma without elevated pressure,” it may be more appropriate to regard it as an opportunity to broaden our understanding of glaucomatous neurodegeneration. Pressure remains an important determinant of mechanical stress on the optic nerve; however, it may represent only one component of a far more complex biological process.
Emerging evidence from ophthalmology, neuroscience, vascular biology and aging research suggests that retinal ganglion cell survival is influenced by multiple interacting factors. Ocular biomechanics, axial length, vascular regulation, mitochondrial function, oxidative stress, immune responses and cellular energy metabolism may all contribute to the vulnerability—or resilience—of the optic nerve.
From this perspective, glaucoma may be understood not solely as a disease of pressure, but as a disease of tissue susceptibility. Two individuals exposed to the same intraocular pressure may not experience the same biological response because the resilience of their optic nerve differs. Understanding the determinants of this resilience may become one of the most important scientific challenges in glaucoma research over the coming decades.
This Vision Paper does not propose a new disease model, nor does it question the established importance of lowering intraocular pressure. Instead, it offers a hypothesis-generating conceptual framework intended to stimulate interdisciplinary discussion. The central proposition is that future research may benefit from integrating pressure-related mechanisms with broader biological concepts, including biomechanics, mitochondrial health, vascular homeostasis and neuroprotection.
The purpose is not to replace existing paradigms, but to complement them.
Perhaps the most important question is therefore no longer:
“How high is the intraocular pressure?”
but rather:
“Why does one optic nerve remain resilient while another progressively degenerates under apparently similar conditions?”
Answering this question may not only improve our understanding of normal-tension glaucoma but also provide broader insights into neurodegeneration, healthy aging and the preservation of neuronal function throughout life.
5.2 Japan Changed the Question: Why Myopia May Matter More Than We Think
One of the most remarkable observations in glaucoma epidemiology originates from Japan. Unlike many Western populations, where elevated intraocular pressure has traditionally dominated clinical attention, the majority of patients diagnosed with primary open-angle glaucoma in Japan present with intraocular pressure within the statistically normal range. This observation has fundamentally influenced Japanese glaucoma research and has shifted scientific interest toward mechanisms beyond pressure alone.
At the same time, Japan is among the countries with the highest prevalence of myopia worldwide. Over recent decades, increasing axial length has become a defining characteristic of large parts of the population, particularly among younger generations. While myopia is primarily recognized as a refractive condition, its anatomical consequences extend far beyond optical correction.
Axial elongation changes the geometry of the entire posterior segment of the eye. The sclera becomes thinner, the optic nerve head is exposed to altered biomechanical forces, and the lamina cribrosa may undergo structural remodeling. These changes do not necessarily cause glaucoma by themselves; however, they may influence the mechanical environment in which retinal ganglion cell axons function throughout life.
This raises an important conceptual question.
If two individuals have identical intraocular pressure but fundamentally different optic nerve anatomy due to differences in axial length, should the biological impact of the same pressure be expected to be identical?
From a biomechanical perspective, the answer may not necessarily be yes.
Pressure is a physical force, but the response to that force depends on the properties of the tissue that receives it. The optic nerve head is not a rigid structure. Its architecture, connective tissue composition, scleral biomechanics and lamina cribrosa characteristics may determine how mechanical stress is distributed and tolerated over decades.
This concept shifts attention from pressure alone toward biological vulnerability.
Rather than asking whether intraocular pressure is statistically normal, future research may increasingly need to ask whether the optic nerve is structurally capable of tolerating that pressure over an entire lifetime.
Such a perspective does not diminish the importance of intraocular pressure. Instead, it suggests that pressure and tissue susceptibility are inseparable components of the same biological equation.
This concept may also help explain why populations with a high prevalence of axial myopia, such as Japan, have become central to research on normal-tension glaucoma. The disease may not simply reflect the absence of elevated pressure, but rather the interaction between normal mechanical load and increased structural vulnerability.
Understanding this interaction could represent one of the next major steps in glaucoma research. It encourages a broader scientific framework in which ocular biomechanics, retinal ganglion cell resilience, vascular regulation and cellular metabolism are investigated together rather than in isolation.
Within this perspective, normal-tension glaucoma becomes more than a subtype of glaucoma. It becomes a model for understanding how anatomical predisposition and biological resilience together determine whether neural tissue remains functional—or progressively degenerates despite apparently normal clinical parameters.
5.3 Cellular Resilience: Why Retinal Ganglion Cells Survive—or Degenerate
If biomechanics helps explain why certain optic nerves are exposed to greater mechanical vulnerability, it still does not answer the central biological question: Why do some retinal ganglion cells survive for decades under similar conditions while others progressively degenerate?
The answer may lie not only in the magnitude of external stress, but also in the intrinsic capacity of neurons to adapt, maintain homeostasis and recover from chronic physiological challenges.
Retinal ganglion cells are among the most metabolically active neurons in the human body. Their long, unmyelinated axons within the retina require a continuous supply of energy to maintain axonal transport, ionic gradients and synaptic communication. This dependence makes them particularly vulnerable to disturbances in mitochondrial function, oxidative balance and cellular metabolism.
Increasing evidence suggests that glaucomatous neurodegeneration cannot be understood solely as a mechanical disorder. Instead, it appears to involve a complex interaction between mechanical stress, vascular regulation, mitochondrial function, oxidative stress, neuroinflammation and age-related decline in cellular repair mechanisms.
Within this broader framework, the concept of cellular resilience becomes increasingly relevant.
Cellular resilience describes the ability of a cell to maintain structural integrity and biological function despite continuous internal and external stress. In retinal ganglion cells, this resilience is likely determined by multiple interconnected systems, including mitochondrial ATP production, antioxidant defense mechanisms, efficient protein turnover, autophagy, immune regulation and adequate microvascular perfusion.
When these adaptive mechanisms function efficiently, neurons may tolerate mechanical stress for many years without clinically detectable damage. When resilience progressively declines, however, the same level of mechanical load may become sufficient to initiate irreversible neurodegeneration.
This perspective may help explain one of the most puzzling observations in glaucoma: similar intraocular pressure does not necessarily result in similar clinical outcomes.
The biological response appears to differ because the tissue itself differs.
From this viewpoint, intraocular pressure should not be regarded as an isolated causal factor but as one component acting upon tissue with varying degrees of biological resilience. Disease progression may therefore depend not only on the external load but also on the capacity of retinal ganglion cells to preserve mitochondrial function, regulate oxidative stress, maintain axonal transport and adapt to chronic metabolic demands.
This conceptual framework also creates an important bridge between glaucoma research and the rapidly expanding fields of aging biology and neurodegeneration. Many biological processes currently investigated in Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders—including mitochondrial dysfunction, impaired cellular energetics, chronic low-grade inflammation and declining stress resistance—may also contribute to the progressive loss of retinal ganglion cells.
Rather than viewing glaucoma exclusively as an ocular disease, it may therefore be valuable to consider it as a localized manifestation of broader biological processes that influence neuronal survival throughout the body.
This perspective does not replace established concepts of pressure reduction. Instead, it complements them by emphasizing that preserving neuronal function may ultimately depend on understanding not only the forces acting upon the optic nerve, but also the biological capacity of the tissue to withstand those forces.
Future research should therefore increasingly integrate ocular biomechanics with mitochondrial biology, vascular physiology, immunology and systems medicine. Such an interdisciplinary approach may help explain why retinal ganglion cells remain resilient in some individuals while progressively degenerate in others despite apparently comparable clinical conditions.
The therapeutic implications of this conceptual framework are discussed in the following chapter, where current treatment strategies and future research directions are considered in light of this broader biological perspective.
Suggested Citation
Paulig S. VISION PAPER™ No. 5: Beyond Intraocular Pressure – Rethinking Normal-Tension Glaucoma Through Biomechanics, Cellular Resilience and Neuroprotection. Vision Paper™ Series. 2026. Available at: www.paulig-eye-health.de
Author’s Note
This Vision Paper presents a hypothesis-generating conceptual framework intended to stimulate interdisciplinary scientific discussion. It should not be interpreted as a clinical guideline or therapeutic recommendation. Clinical decisions should always be based on current evidence, established guidelines and individual patient circumstances.
06.08.2026
Copyright
© 2026 Sylvia Paulig. All rights reserved.
No part of this publication may be reproduced, distributed, translated, or stored in any retrieval system without prior written permission of the author, except for brief quotations used for scientific citation, review, or educational purposes in accordance with applicable copyright law. Patient Care. National Academies Press.
VISION PAPER NO.6
VISION PAPER™ No. 6
Beyond Pressure Reduction
Rethinking Glaucoma Therapy Through Cellular Protection and Metabolic Resilience
6.1 Lowering Pressure Is Essential — But Is It Enough?
For decades, glaucoma therapy has been built around one central therapeutic target: intraocular pressure (IOP).
And for good reason.
Lowering IOP remains the only therapeutic intervention that has consistently been shown to reduce the risk of glaucomatous progression and preserve visual function. This applies even to normal-tension glaucoma, where pressure values are already within what has traditionally been considered the normal range.
The landmark Collaborative Normal-Tension Glaucoma Study demonstrated that lowering IOP by approximately 30% significantly reduced the likelihood of progression in patients with normal-tension glaucoma.
This finding fundamentally changed our understanding of the disease: even a pressure that is statistically “normal” may still be biologically too high for an individual optic nerve.
But it also revealed something equally important.
Pressure reduction does not explain everything.
Some patients continue to lose retinal nerve fibre layer, retinal ganglion cells and visual function despite apparently well-controlled intraocular pressure. Conversely, some patients with normal-tension glaucoma remain remarkably stable for years.
This heterogeneity raises a fundamental question:
If pressure were the entire disease, why does lowering pressure not protect every patient?
Perhaps the answer lies in distinguishing between a risk factor and the biological vulnerability of the tissue exposed to that risk factor.
The same mechanical load may be tolerated by one optic nerve and not by another.
The same intraocular pressure may therefore represent very different biological stresses depending on the structural, vascular and metabolic resilience of the individual eye.
This becomes particularly relevant in normal-tension glaucoma.
Here, the therapeutic paradox becomes visible: we lower a pressure that was never elevated in the conventional sense because doing so reduces one component of stress on an already vulnerable system.
That is rational and evidence-based.
But it may not be sufficient.
Normal-Tension Glaucoma Is No Longer a Marginal Phenomenon
Normal-tension glaucoma was once regarded primarily as an unusual subtype of primary open-angle glaucoma.
Epidemiological evidence increasingly challenges this perception.
While reported proportions of normal-tension glaucoma among primary open-angle glaucoma are substantially lower in Western populations, studies from East Asia have repeatedly reported dramatically higher proportions. In several Asian populations, the majority of patients diagnosed with primary open-angle glaucoma have intraocular pressure within the statistically normal range.
In Japan, landmark population-based data have suggested proportions exceeding 90%.
This observation deserves more than epidemiological attention.
If glaucomatous optic neuropathy can so frequently develop without conventionally elevated intraocular pressure, elevated pressure cannot be considered a universal explanation for the disease.
It remains an important and modifiable risk factor.
But risk factor and disease mechanism are not synonymous.
The Diagnostic Blind Spot: Do We Find What We Look For?
The striking prevalence of normal-tension glaucoma in East Asian populations is commonly interpreted as evidence of geographical or biological differences.
This may indeed be part of the explanation.
Genetic background, myopia and axial length, vascular regulation and other population-specific factors may contribute to the particularly high prevalence reported in Japan and other Asian countries.
But there is another possibility that deserves greater attention:
Do we find what we actively look for?
Normal-tension glaucoma is inherently more difficult to detect within a diagnostic system historically centred on elevated intraocular pressure.
When pressure is elevated, it immediately raises suspicion. Further examination follows.
When pressure is normal, however, this diagnostic trigger disappears.
The consequence may be substantial underdiagnosis.
European data support this concern.
Population-based screening studies have demonstrated that a considerable proportion of glaucoma remains undiagnosed. More importantly, studies comparing systematic screening with routine clinical detection have found markedly higher proportions of normal-tension glaucoma when populations are actively examined for glaucomatous damage rather than selected primarily through elevated intraocular pressure.
In one European screening study, 52.9% of glaucoma detected through systematic screening was classified as normal-tension glaucoma, compared with only 13.5% among patients identified through routine clinical pathways.
More recent European population data reinforce the broader diagnostic problem. A large 2025 analysis comprising 55,415 participants from 14 population-based European studies found that 56.4% of individuals identified as having glaucoma had previously been undiagnosed.
These observations raise an important epidemiological question.
The lower reported prevalence of normal-tension glaucoma in Europe compared with East Asia may reflect genuine biological differences.
But it may also partly reflect differences in how intensively we search for glaucoma when intraocular pressure is normal.
Epidemiological statistics do not only describe biology.
They also reflect diagnostic behaviour.
A disease phenotype that is systematically searched for will be detected more frequently than one that remains outside the primary diagnostic focus.
The extraordinarily high proportion of normal-tension glaucoma reported in Japan should therefore not simply lead us to conclude that normal-tension glaucoma is predominantly an Asian phenomenon.
It should provoke another question:
What would the epidemiology of glaucoma in Europe look like if we searched as systematically for neurodegeneration at normal intraocular pressure?
From Measuring Pressure to Detecting Neurodegeneration
This question becomes particularly important in the era of optical coherence tomography.
We are no longer dependent on elevated pressure or advanced visual field loss to alert us to disease.
Structural neuronal loss can increasingly be identified and followed through careful assessment of the optic nerve, retinal nerve fibre layer and ganglion cell structures before substantial functional impairment becomes apparent.
If structural damage is not actively sought, however, a patient with normal intraocular pressure may remain invisible to a pressure-centred diagnostic pathway for years.
The diagnostic paradigm can therefore change:
from searching primarily for elevated pressure to searching for early neurodegeneration.
And if the way we search changes, the epidemiology we observe may change with it.
From Pressure Control to Biological Resilience
The retinal ganglion cell does not live in isolation from the rest of human biology.
Its survival depends on energy production, mitochondrial integrity, axonal transport, vascular supply, oxygen delivery, redox balance, inflammatory regulation and the capacity to respond to cellular stress.
A neuron with sufficient energetic reserve may tolerate a certain degree of mechanical or vascular stress.
A metabolically compromised neuron may not.
This suggests that glaucoma therapy may need to evolve from a predominantly pressure-centred model toward a broader concept:
Reduce the stress — and strengthen the cell.
These are not competing strategies.
IOP reduction remains essential.
The question is whether the next generation of glaucoma therapy should complement it by identifying and addressing the factors that determine why one retinal ganglion cell survives while another degenerates.
Instead of asking only:
“How much further can we lower the pressure?”
we may also need to ask:
“What is making this optic nerve vulnerable?”
And perhaps even more fundamentally:
“Why does an optic nerve degenerate when intraocular pressure was never pathologically elevated in the first place?”
These questions open a much wider therapeutic landscape.
They direct attention toward ocular perfusion and vascular autoregulation. Toward mitochondrial energy production and oxidative stress. Toward neuroinflammation, metabolic resilience and systemic factors that may influence the biological environment of the optic nerve.
Not all of these pathways have yet translated into established clinical therapies. Neuroprotective strategies remain an active field of research, and current glaucoma guidelines appropriately continue to regard IOP reduction as the only intervention proven to preserve visual function.
But the absence of an established therapy does not mean that the underlying biology should be ignored.
It means that the next therapeutic frontier has not yet been fully defined.
The history of glaucoma treatment has taught us how to reduce pressure.
The next challenge may be to understand how to preserve the neuron that pressure reduction is intended to protect.
The future of glaucoma therapy may therefore not be a choice between pressure reduction and neuroprotection.
It may be their integration.
Pressure remains a modifiable stressor.
But cellular resilience may determine how successfully the optic nerve survives that stress.
And if that is true, the therapeutic goal of the future will extend beyond achieving a target pressure.
It will be to create the biological conditions in which retinal ganglion cells have the greatest possible chance to survive.
6.2 SLT: More Than Pressure Reduction?
Selective laser trabeculoplasty is generally classified as a pressure-lowering treatment.
Clinically, this is correct.
Biologically, however, it may be an incomplete description.
SLT does not simply create a mechanical opening through which aqueous humor can escape. Unlike older concepts of laser trabeculoplasty based predominantly on structural or thermal effects, SLT appears to initiate a complex biological response within the trabecular meshwork.
This distinction may be more important than we have traditionally assumed.
The Trabecular Meshwork Is Living Tissue
The trabecular meshwork is not merely a passive drainage filter.
It is a metabolically active and dynamically regulated tissue involved in maintaining aqueous humor outflow and intraocular pressure homeostasis.
Its endothelial-like cells interact with extracellular matrix, respond to mechanical and biochemical signals and possess phagocytic capacity.
With aging and glaucoma, this system can change.
Trabecular cellularity may decline. Extracellular matrix turnover may become disturbed. Tissue stiffness can increase. Cellular stress, fibrosis and impaired phagocytic function may progressively alter the resistance of the conventional outflow pathway.
From this perspective, glaucoma treatment should not only ask how aqueous humor can bypass resistance.
It should also ask whether the function of the tissue creating that resistance can be restored.
SLT Initiates a Biological Response
Experimental evidence increasingly supports such a concept.
Following SLT, monocytes are recruited into the trabecular meshwork. Experimental studies have demonstrated a several-fold increase in monocyte recruitment following laser treatment.
These monocytes and macrophages are not passive bystanders.
They appear to participate in aqueous outflow regulation.
Experimental studies have demonstrated that monocytes and monocyte-derived factors can increase outflow facility and alter the conductivity of Schlemm’s canal endothelial cells.
SLT also induces cytokine signalling within the conventional outflow pathway.
This signalling may influence extracellular matrix remodelling, cellular permeability and communication between trabecular meshwork cells and Schlemm’s canal endothelial cells.
The pressure-lowering effect of SLT may therefore emerge from a coordinated biological response rather than from a purely mechanical laser effect.
This changes the way we can think about the procedure.
From Laser Treatment to Tissue Response
If SLT recruits immune cells, modifies cytokine signalling and stimulates extracellular matrix remodelling, then its therapeutic effect may be understood as a form of controlled biological activation of the outflow system.
The innate immune system may play a particularly interesting role.
Macrophages are among the body’s fundamental mechanisms for recognising, processing and removing damaged cellular material.
Within the trabecular meshwork, such activity may contribute to restoring a more functional environment for aqueous outflow.
Recent experimental work adds another dimension.
In human trabecular meshwork cells exposed to glucocorticoids, SLT has been shown to reduce fibrotic and myofibroblast-like changes while partially restoring impaired phagocytosis and cellular proliferation.
These findings do not prove that SLT regenerates the trabecular meshwork in patients.
But they reinforce an important principle:
SLT can influence cellular behaviour, not only intraocular pressure.
From Clinical Observation to a Testable Hypothesis
Our clinical experience with selective laser trabeculoplasty began in 2007.
Over time, and particularly in patients with normal-tension glaucoma, an observation increasingly challenged a purely pressure-centred interpretation of SLT.
The question was no longer simply whether intraocular pressure decreased after treatment.
We began to ask whether the biological response induced within the trabecular meshwork itself might be therapeutically relevant.
This question became particularly important during long-term structural follow-up using optical coherence tomography.
In patients in whom retinal nerve fibre layer loss could be followed over time, the relationship between intraocular pressure and structural progression was not always straightforward.
Some eyes continued to deteriorate despite apparently acceptable pressure values, while others appeared structurally more stable than pressure measurements alone would have predicted.
From these observations emerged a working hypothesis:
Could SLT influence the biological environment of the eye in ways that are not completely captured by measuring intraocular pressure alone?
One potential mechanism attracted particular attention: activation and recruitment of monocytes and macrophages within the trabecular meshwork.
The concept was biologically compelling.
Macrophages are not simply inflammatory cells. They are fundamental components of tissue surveillance, clearance and repair. Their capacity to phagocytose cellular debris and participate in extracellular matrix turnover suggested that their recruitment after SLT might contribute to restoring a more functional trabecular environment.
This led us to consider SLT increasingly as a potential form of biological activation and tissue cleaning, rather than exclusively as a pressure-lowering laser procedure.
Importantly, this interpretation initially arose from clinical observation and biological reasoning.
Subsequent and evolving experimental research has increasingly provided mechanistic support for parts of this concept.
Studies have demonstrated a several-fold recruitment of monocytes into the trabecular meshwork following SLT. Monocytes and macrophages have been shown experimentally to increase aqueous outflow facility and alter Schlemm’s canal endothelial conductivity.
Further research has expanded this biological model toward cytokine signalling, extracellular matrix remodelling, phagocytic function and restoration of trabecular cellular behaviour.
These findings do not prove that SLT directly protects retinal ganglion cells.
Nor do they establish that macrophage activation in the anterior chamber independently prevents RNFL loss.
That remains our hypothesis — and an important distinction.
But the convergence between long-term clinical observation and increasingly detailed experimental evidence raises a question that deserves prospective investigation:
Could SLT Exert Disease-Modifying Effects That Are Not Adequately Described by the Magnitude of IOP Reduction Alone?
If so, the relevant endpoint for future studies should not be pressure alone.
It should include longitudinal structural outcomes:
RNFL thickness. Ganglion cell integrity. Rate of progression. And ultimately, preservation of neuronal function.
This distinction is particularly important in normal-tension glaucoma, where the pressure reduction achieved by SLT may be numerically modest precisely because baseline pressure is already low.
If treatment success is defined exclusively by millimetres of mercury, a biologically meaningful response could potentially remain invisible.
The hypothesis therefore does not replace the established pressure-lowering mechanism of SLT.
It extends the question.
Perhaps the most important effect of SLT is not only what happens to pressure — but what happens to the tissue after the laser pulse has disappeared.
Experimental Models and Human Clinical Observation
Some of the most exciting developments in retinal ganglion cell protection and regeneration currently originate from experimental research.
Work at Harvard Medical School and Mass Eye and Ear has demonstrated in mouse models that retinal ganglion cells may retain a previously underestimated capacity for biological restoration.
Experimental epigenetic reprogramming using Oct4, Sox2 and Klf4 has promoted axonal regeneration and restored visual function in models of optic nerve injury, ageing and glaucoma.
These findings are remarkable.
They challenge the long-standing assumption that neuronal damage in the adult visual system is necessarily irreversible and open an entirely new field of regenerative ophthalmology.
But they also illustrate an important principle in translational medicine:
Experimental evidence and human clinical observation should not compete with each other. They should inform each other.
Animal models allow mechanisms to be isolated, manipulated and investigated with a precision that is often impossible in humans.
Clinical medicine provides something different.
It allows us to observe what happens in the complex biological system of the human patient — repeatedly, longitudinally and sometimes over many years.
In our own clinical work, structural OCT and RNFL observations following SLT in patients with normal-tension glaucoma have accumulated over almost a decade.
These observations were not generated in an experimental mouse model.
They arose in human eyes under real clinical conditions.
They do not constitute randomized proof that SLT induces retinal ganglion cell regeneration or IOP-independent neuroprotection.
We should not claim that they do.
But neither should long-term clinical observations in humans be dismissed simply because the underlying mechanism has not yet been fully demonstrated experimentally.
Clinical observation has historically preceded mechanistic explanation in many areas of medicine.
The scientifically appropriate response to an unexpected and reproducible clinical observation is therefore neither premature certainty nor premature rejection.
It is investigation.
If repeated longitudinal OCT observations suggest structural stabilization — or potentially changes that cannot be adequately explained by pressure reduction alone — these findings should generate prospective hypotheses and controlled studies.
This becomes particularly relevant at a time when experimental research itself is questioning long-held assumptions about the regenerative capacity of retinal ganglion cells.
Mouse studies cannot prove what occurs in the human optic nerve.
But neither can the absence of an established molecular explanation negate years of observations made directly in human patients.
The two approaches should meet.
Experimental research can identify mechanisms.
Long-term clinical observation can identify phenomena worth explaining.
The next step should therefore be prospective validation: standardized OCT endpoints, defined SLT protocols, carefully characterized normal-tension glaucoma populations, longitudinal RNFL and ganglion cell analysis, and appropriate control groups.
Only then can we determine whether the structural observations seen clinically represent pressure-mediated stabilization, altered rates of neurodegeneration, biological effects beyond IOP reduction — or potentially something we have not yet adequately defined.
Why a VISION PAPER™ Matters
This is also where the concept of the VISION PAPER™ becomes relevant.
Scientific progress depends on evidence.
But evidence begins with a question.
Not every important observation originates within a university department, a large research consortium or an established academic programme.
Questions may emerge from decades of clinical practice, from repeated observations in patients, from unexpected findings or from connections between disciplines that have not previously been considered together.
Such observations should not be confused with proof.
But neither should they have to wait for institutional validation before they can be articulated as hypotheses.
Traditional scientific publishing performs an indispensable function. Peer review, methodological scrutiny, reproducibility and independent validation are essential when a hypothesis is to become scientific evidence.
Yet the pathway from an initial observation to a funded study, completed experiment, peer-reviewed manuscript and final publication can take years.
In rapidly developing fields, this creates an important gap between what clinicians and scientists are beginning to observe and what the literature is already able to establish.
The VISION PAPER™ is intended to occupy precisely this space.
It does not replace the scientific paper.
It precedes, connects and challenges it.
It provides a platform in which clinical observations, biological reasoning and emerging scientific evidence can be brought together transparently — with a clear distinction between what is known, what has been observed and what is hypothesized.
This distinction is fundamental.
A hypothesis does not become more valid because it originates from a prestigious institution.
Nor does a clinical observation become irrelevant because its mechanism has not yet been published.
Science advances when observations can be expressed, questioned, tested and, where necessary, rejected.
The purpose of a VISION PAPER™ is therefore not to bypass scientific standards.
It is to accelerate the generation of questions worthy of scientific testing.
This may be particularly important in medicine, where clinicians sometimes observe patterns in human patients years before the experimental tools, institutional structures or prospective studies required to explain them become available.
Editors, universities and peer-reviewed journals remain essential for validating evidence.
But the generation of ideas should remain open.
Scientific authority validates evidence.
It should not determine who is allowed to ask the question.
The faster meaningful observations can be transformed into testable hypotheses, the faster research can decide whether they are right or wrong.
And ultimately, that is what scientific progress requires.
A Broader Concept of Ocular Homeostasis
The eye is a biological system in continuous exchange.
Aqueous humor is produced, circulates through the anterior chamber and leaves primarily through the trabecular meshwork and Schlemm’s canal.
The integrity of this pathway depends on living cells, extracellular matrix turnover, signalling molecules and immune surveillance.
Disturbance of such a system may therefore be more than a plumbing problem.
And restoring its function may be more than opening a drain.
This leads to a broader interpretation of SLT:
not simply as a laser that lowers pressure, but as an intervention capable of initiating a biological response within a dysfunctional outflow tissue.
Whether this response has consequences beyond aqueous outflow remains an open scientific question.
But it is precisely this question that deserves investigation.
Because if glaucoma — particularly normal-tension glaucoma — is increasingly understood as a disease involving cellular vulnerability, mitochondrial dysfunction, vascular regulation and impaired resilience, then treatment may ultimately need to operate on several biological levels simultaneously.
SLT may provide an instructive example of this transition.
We began using it because it lowers pressure.
We may eventually understand it more completely by asking what it does to the tissue itself.
And this leads directly to the next therapeutic question:
If cellular resilience determines whether a retinal ganglion cell survives, can we actively strengthen that resilience?
6.3 The Mitochondrion as a Therapeutic Target
If intraocular pressure does not fully explain why retinal ganglion cells degenerate, the next question must move deeper into the cell.
What determines whether a retinal ganglion cell can survive stress?
Increasingly, one answer points toward the mitochondrion.
Mitochondria are often described as the powerhouses of the cell.
For retinal ganglion cells, however, this description is almost too simple.
These neurons have exceptionally high energetic demands. They must maintain membrane potentials, generate action potentials, transport proteins and organelles along long axons, preserve synaptic function and continuously adapt to mechanical, vascular and metabolic stress.
All of this requires energy.
And much of that energy depends on mitochondrial function.
The question of glaucoma may therefore not only be how much stress reaches the retinal ganglion cell.
It may also be:
How much metabolic reserve does the cell have when that stress arrives?
Glaucoma as an Energetic Vulnerability
A retinal ganglion cell does not necessarily die because one single damaging event occurs.
Degeneration may result when multiple stresses converge on a cell whose capacity to compensate has progressively diminished.
Mechanical strain at the lamina cribrosa, impaired ocular perfusion, oxidative stress, disturbed axonal transport, neuroinflammation and ageing may all increase energetic demand while simultaneously reducing the cell’s ability to meet it.
This creates a potentially dangerous mismatch:
energy demand rises while energy reserve falls.
Mitochondrial dysfunction is increasingly recognised as an important component of this vulnerability.
Altered oxidative phosphorylation, impaired mitochondrial dynamics, defective mitophagy and increased production of reactive oxygen species have all been implicated in retinal ganglion cell degeneration.
This may be particularly relevant in normal-tension glaucoma.
If pressure is not markedly elevated, another question becomes unavoidable:
Could some optic nerves fail not because the mechanical stress is extraordinarily high, but because their biological capacity to tolerate ordinary stress has become extraordinarily low?
This represents a fundamentally different therapeutic perspective.
ATP: The Energy Required to Survive
ATP is not simply cellular fuel.
It is required for maintaining ionic gradients, axonal transport, synaptic transmission, protein turnover and repair mechanisms.
The retinal ganglion cell and its long axon are particularly dependent on continuous energy availability.
When mitochondrial ATP production becomes insufficient, several processes may begin to fail simultaneously.
Axonal transport can become impaired.
Ion homeostasis becomes more difficult to maintain.
Oxidative damage accumulates.
Cellular repair mechanisms become less effective.
And eventually, pathways leading toward axonal degeneration and apoptosis may be activated.
This suggests that metabolic failure may not merely accompany neurodegeneration.
It may contribute to the transition from a stressed but viable neuron to an irreversibly damaged one.
NAD⁺: More Than a Metabolic Molecule
One of the most interesting developments in glaucoma research concerns nicotinamide adenine dinucleotide — NAD⁺.
NAD⁺ is essential for cellular redox reactions and mitochondrial energy production.
But its biological significance extends considerably further.
It participates in cellular stress responses, DNA repair and signalling pathways involving sirtuins and other enzymes that regulate cellular survival and adaptation.
Experimental glaucoma research has demonstrated disturbances in NAD metabolism and has suggested that retinal ganglion cells may become increasingly vulnerable as NAD availability declines.
This has led to considerable interest in nicotinamide, a precursor of NAD⁺, as a potential neuroprotective strategy.
Preclinical studies have produced striking results.
Nicotinamide supplementation has protected retinal ganglion cell somas, dendrites and axons in several experimental models and has been associated with improved mitochondrial function and resistance to metabolic stress.
Human evidence, however, remains preliminary.
Early phase clinical trials have shown encouraging physiological and functional signals, but current evidence is not sufficient to establish nicotinamide as a proven neuroprotective treatment for glaucoma.
This distinction is important.
Biological plausibility is not the same as clinical proof.
But biological plausibility tells us where to look.
Oxidative Stress: Cause, Consequence — or Both?
Mitochondrial dysfunction and oxidative stress are closely connected.
Mitochondria generate reactive oxygen species as a normal consequence of cellular respiration.
Under physiological conditions, antioxidant defence systems maintain these molecules within a controlled range.
When mitochondrial function deteriorates, however, reactive oxygen species may increase beyond the cell’s capacity to neutralise them.
Proteins, lipids, mitochondrial membranes and DNA can then become damaged.
This creates the possibility of a self-amplifying cycle:
mitochondrial dysfunction → oxidative stress → mitochondrial damage → further energetic failure.
In glaucoma, oxidative stress has been described not only in the posterior segment and retinal ganglion cells but also within the trabecular meshwork.
This is an intriguing connection to the preceding discussion of SLT.
The anterior and posterior segments may not represent completely independent biological problems.
A dysfunctional outflow system and a vulnerable retinal ganglion cell may both reflect aspects of ageing, oxidative burden, impaired cellular clearance and declining biological resilience.
This does not mean that one necessarily causes the other.
But it suggests that glaucoma may need to be understood as more than a local pressure disorder.
Resveratrol and the Question of Cellular Resilience
This broader biological perspective has influenced our own therapeutic thinking for many years.
Alongside pressure management and SLT, we became increasingly interested in whether metabolic and mitochondrial support could help create a more favourable biological environment for retinal ganglion cell survival.
One molecule of particular interest has been resveratrol.
Resveratrol interacts with several pathways relevant to cellular stress responses, including SIRT1-related signalling, AMPK, oxidative stress regulation, inflammation and mitochondrial function.
Experimental glaucoma and retinal injury studies have reported protective effects on retinal ganglion cells, including reduced oxidative stress and apoptosis and improved cell survival.
More recent systematic analyses of preclinical studies have strengthened the biological rationale, reporting improved retinal ganglion cell survival and preservation of retinal structure across experimental models.
But here again, scientific precision is essential.
Most of this evidence remains preclinical.
It does not prove that oral resveratrol prevents glaucoma progression or regenerates retinal ganglion cells in humans.
Our clinical use and observations therefore represent a translational hypothesis rather than an established guideline-based neuroprotective treatment.
Yet the increasing convergence between mitochondrial biology, oxidative stress research, SIRT1-related pathways and retinal ganglion cell survival makes this hypothesis increasingly worthy of prospective investigation.
The relevant question is no longer simply whether resveratrol is an “antioxidant.”
That description may be too narrow.
The more interesting question is whether interventions influencing cellular energy regulation and stress-response pathways can alter the resilience of the neuron itself.
From Neuroprotection to Metabolic Neuroprotection
The term neuroprotection has been used in glaucoma for decades.
Yet many previous approaches focused on blocking a single downstream mechanism of neuronal injury.
The failure of some major neuroprotection trials should not necessarily be interpreted as evidence that neuroprotection itself is impossible.
It may indicate that the biological target, timing, endpoint or therapeutic strategy was incomplete.
A metabolically compromised neuron is unlikely to be rescued simply by blocking one final pathway of cell death.
Perhaps intervention must occur earlier.
Before irreversible structural loss.
Before energetic reserve is exhausted.
Before the axon reaches the point of no return.
This suggests a different concept:
Metabolic Neuroprotection
Instead of attempting only to inhibit neuronal death, metabolic neuroprotection would aim to maintain the biological capacity of the neuron to resist stress.
Potential targets include:
mitochondrial function,
NAD⁺ availability,
ATP production,
oxidative stress regulation,
mitophagy,
axonal transport,
cellular stress-response pathways,
and vascular delivery of oxygen and metabolic substrates.
These mechanisms are interconnected.
And this may explain why a single intervention is unlikely to provide the complete answer.
Treating the Vulnerability, Not Only the Stressor
This brings us back to the central argument of this VISION PAPER™.
Pressure reduction reduces an important stressor.
SLT may additionally modify the biology of the outflow tissue.
But neither approach directly answers the question of why one retinal ganglion cell survives and another does not.
Mitochondrial biology introduces another therapeutic dimension:
the resilience of the target cell itself.
The emerging literature increasingly supports this shift. Mitochondrial dysfunction, NAD⁺ depletion, oxidative stress and impaired metabolic adaptation are now being investigated not merely as consequences of glaucoma but as potential contributors to retinal ganglion cell vulnerability.
And early clinical research is beginning to move beyond animal models.
NAD⁺-supporting interventions, metabolic therapies and other mitochondrial strategies are entering human studies. Preliminary clinical observations are appearing, although robust evidence of long-term structural neuroprotection remains absent.
This is exactly the stage at which scientific caution and scientific curiosity must coexist.
We should not present emerging metabolic interventions as proven glaucoma therapy.
But neither should we wait until retinal ganglion cells are irreversibly lost before asking whether their metabolic resilience could have been supported.
The therapeutic paradigm may therefore need to evolve:
Lower the pressure.
Restore ocular homeostasis.
Protect mitochondrial function.
Preserve cellular energy.
Strengthen neuronal resilience.
Not one instead of the other.
All as components of a more complete biological strategy.
Because ultimately, the objective of glaucoma treatment is not to achieve a particular number on a tonometer.
It is to keep the retinal ganglion cell alive.
6.4 From Neuroprotection to a Clinical Strategy
If mitochondrial dysfunction, impaired energy metabolism and reduced cellular resilience contribute to retinal ganglion cell vulnerability, the next question is unavoidable:
How can this knowledge be translated into clinical practice?
This is where caution becomes particularly important.
The biological rationale for neuroprotection in glaucoma is becoming increasingly compelling. Yet the evidence supporting individual neuroprotective interventions in humans remains substantially less developed than the evidence supporting intraocular pressure reduction.
The objective should therefore not be to replace established glaucoma therapy with experimental concepts.
It should be to ask whether established treatment can be embedded within a broader strategy designed to preserve the biological environment of the retinal ganglion cell.
Not One Treatment — but Several Levels of Protection
Glaucoma is unlikely to be successfully addressed by a single therapeutic mechanism.
If retinal ganglion cell degeneration results from the interaction of mechanical stress, vascular dysregulation, mitochondrial dysfunction, oxidative stress, impaired axonal transport, neuroinflammation and declining metabolic reserve, then treatment may ultimately need to operate on several levels simultaneously.
This suggests a layered therapeutic concept:
reduce mechanical stress,
improve ocular homeostasis,
identify vascular vulnerability,
support cellular energy metabolism,
reduce avoidable metabolic stress,
and monitor neuronal structure before irreversible function is lost.
The individual components are not equally established.
Some are already standard clinical practice.
Others are supported primarily by mechanistic or experimental evidence.
And some remain hypotheses requiring prospective validation.
The important point is not to confuse these levels of evidence.
It is to connect them.
Level 1: Reduce the Established Stressor
Intraocular pressure reduction remains the foundation of glaucoma treatment.
Medication, SLT and surgical procedures have established roles according to the individual patient’s disease severity, target pressure and risk of progression.
Nothing in a metabolic or neuroprotective concept diminishes this.
On the contrary:
If the retinal ganglion cell is vulnerable, reducing unnecessary mechanical stress becomes even more important.
But normal-tension glaucoma demonstrates the limitation of stopping there.
When progression occurs despite apparently adequate pressure control, repeatedly lowering IOP without investigating the biological context may address only one component of the problem.
Level 2: Look for the Vulnerable Patient
A broader therapeutic strategy begins with a broader diagnostic strategy.
Not every patient with the same RNFL thickness, visual field defect or intraocular pressure has the same biological risk.
Particular attention may be warranted when structural progression appears disproportionate to pressure.
Potential contributors include impaired ocular perfusion, excessive nocturnal blood pressure reduction, vascular dysregulation, sleep-related abnormalities, metabolic dysfunction, nutritional deficiencies and other systemic factors capable of influencing neuronal energy supply or cellular stress.
This does not mean that every patient with glaucoma requires an indiscriminate battery of laboratory investigations.
It means that:
progression unexplained by pressure should trigger a search for what pressure does not explain.
The patient should not disappear behind the tonometry value.
Level 3: Protect Perfusion Without Simplifying It
Ocular perfusion represents one of the most compelling additional dimensions in normal-tension glaucoma.
The optic nerve requires continuous delivery of oxygen and metabolic substrates.
But perfusion is not simply equivalent to systemic blood pressure.
It depends on vascular autoregulation, endothelial function, local vascular resistance, nocturnal haemodynamics and the ability of the microcirculation to adapt to changing metabolic demand.
Both insufficient perfusion and unstable perfusion may matter.
This is particularly relevant at night.
A patient whose intraocular pressure appears excellent during daytime consultation may simultaneously experience substantial nocturnal systemic hypotension.
In such a situation, lowering pressure further may still be appropriate — but it may not address the complete physiological problem.
This argues for greater communication between ophthalmology and general medicine.
The optic nerve does not know which medical specialty is responsible for its blood supply.
Level 4: Support Metabolic Resilience — Without Pretending the Evidence Is Complete
The emerging field of metabolic neuroprotection introduces several potential therapeutic targets.
NAD⁺ metabolism and nicotinamide are currently among the most actively investigated.
Coenzyme Q10 has attracted interest because of its role in mitochondrial electron transport and antioxidant defence.
Citicoline has been investigated for effects on neuronal membranes, neurotransmission and retinal ganglion cell function.
Resveratrol has attracted attention through pathways involving SIRT1, AMPK, mitochondrial function, oxidative stress and inflammatory regulation.
Other strategies targeting mitochondrial biogenesis, mitophagy, redox regulation and cellular energy metabolism are under investigation.
These approaches should not currently be presented as equivalent to established pressure-lowering therapy.
But neither should they all be dismissed under the imprecise label of “supplements.”
The relevant scientific question is not whether a substance belongs to a pharmaceutical or nutritional category.
It is:
Does it modify a biological pathway relevant to retinal ganglion cell survival, at an effective concentration, with acceptable safety — and can that effect ultimately be demonstrated in humans?
That question requires research.
Resveratrol: From Biological Rationale to Clinical Observation
Our own interest in resveratrol developed from precisely this perspective.
We have used resveratrol as part of a broader metabolic strategy in patients with glaucomatous neurodegeneration, particularly in combination with SLT and longitudinal OCT monitoring.
The rationale was not based simply on its frequently cited antioxidant properties.
Of greater interest were pathways associated with cellular stress adaptation and mitochondrial function, including SIRT1, AMPK and PGC-1α-related signalling.
These pathways are involved in mitochondrial biogenesis, energy regulation, oxidative stress responses and cellular survival.
Over years of clinical observation, this combination of pressure management, SLT and metabolic support has contributed to a working hypothesis:
Could improving the biological resilience of the retinal ganglion cell alter the trajectory of structural degeneration?
Again, observation is not proof.
Without randomized controls, changes in RNFL trajectory cannot automatically be attributed to resveratrol, SLT-induced biological effects or any single component of a multimodal strategy.
Regression to the mean, measurement variability, pressure reduction and the natural heterogeneity of glaucoma progression must all be considered.
But repeated observations can identify patterns.
And patterns can generate hypotheses worthy of formal investigation.
This is precisely where clinical medicine can contribute to the research process.
OCT-Guided Biological Intervention
These longitudinal observations have led us toward a concept that we propose to describe as OCT-Guided Biological Intervention.
Rather than allowing intraocular pressure alone to determine when treatment should be initiated or repeated, longitudinal OCT becomes an active component of therapeutic decision-making.
The individual trajectory of RNFL and ganglion cell structures is followed over time.
When renewed structural decline becomes reproducible, the question is not only whether pressure should be lowered further, but whether the biological environment of the eye should be therapeutically addressed again.
In our clinical approach, this has included repeat SLT combined with resveratrol-based metabolic support, followed by renewed structural monitoring.
OCT therefore changes its role: from a diagnostic instrument documenting damage to a longitudinal biological feedback tool guiding intervention.
This concept does not imply that every fluctuation in RNFL thickness should trigger treatment.
Reproducibility, segmentation quality, measurement variability and the complete clinical picture remain essential.
But when a consistent structural trajectory changes, OCT may provide information that precedes clinically apparent functional loss.
OCT-Guided Biological Intervention therefore proposes a dynamic therapeutic model: observe the neuron, identify renewed structural vulnerability, intervene when appropriate, and measure the biological response longitudinally.
This concept requires prospective validation.
But it offers a framework for moving glaucoma management from fixed treatment algorithms toward an individualized response to the behaviour of the patient’s own neuronal tissue.
Repeated Intervention — and a Repeated Structural Observation
An additional observation became particularly relevant during longitudinal follow-up.
In some patients, an initial increase or stabilization of RNFL thickness following SLT and metabolic support was not necessarily permanent.
When subsequent OCT examinations again demonstrated a decline in RNFL thickness, we did not automatically interpret this as the end of therapeutic opportunity.
Instead, SLT was repeated, accompanied by resveratrol-based metabolic support.
In a number of these longitudinally observed eyes, we subsequently observed another increase in measured RNFL thickness.
The significance of this observation should be interpreted carefully.
An increase in OCT-measured RNFL thickness cannot, by itself, be equated with regeneration of retinal ganglion cells. Measurement variability, segmentation effects, changes in tissue characteristics and other confounding factors must be considered.
Nevertheless, the observation becomes more difficult to dismiss when a similar structural pattern appears repeatedly in temporal association with repeated intervention.
This creates an important hypothesis:
If structural decline can be followed by stabilization or an increase in measured RNFL thickness after an intervention — and if a similar response can be observed again after renewed decline and repeated treatment — are we observing only measurement variability, or are we influencing a modifiable biological process?
The question becomes particularly relevant because SLT itself is a repeatable intervention.
When performed appropriately and with controlled energy, repeat SLT can be used when its effect diminishes or when further treatment becomes necessary.
This creates the possibility of thinking about SLT not necessarily as a single lifetime event, but as an intervention that may be reconsidered according to longitudinal structural and clinical findings.
Our clinical approach has therefore increasingly been guided not only by a fixed treatment schedule, but by longitudinal OCT behaviour.
When RNFL measurements suggested renewed structural decline, this became a reason to reassess the biological and therapeutic situation rather than simply wait for further loss.
The combination of repeated SLT, metabolic support and subsequent structural observation does not establish causality.
But the apparent reproducibility of the pattern makes it scientifically relevant.
A single unexpected observation may be incidental.
A repeatedly observed response following repeated intervention becomes a hypothesis that deserves to be tested.
The longitudinal pattern can therefore be conceptualized as:
Structural decline → biological intervention → OCT response → longitudinal observation → renewed decline → repeated intervention → renewed OCT response.
Future prospective studies should examine not only whether SLT lowers intraocular pressure after initial and repeated treatment, but whether repeated intervention is associated with reproducible changes in the rate and direction of longitudinal RNFL and ganglion cell trajectories.
This could help distinguish measurement variability and pressure-mediated stabilization from a potentially broader biological response.
Until such studies are performed, the interpretation must remain cautious.
But the observation itself should not be ignored.
The Endpoint Must Change
If future glaucoma research is to test metabolic neuroprotection, the choice of endpoints becomes critical.
Waiting for advanced visual field deterioration may be too late to understand early biological effects.
Modern OCT allows us to observe structural change longitudinally.
RNFL thickness, macular ganglion cell parameters and rates of structural progression can therefore become important components of prospective neuroprotection studies.
But even OCT requires careful interpretation.
Stabilization is not regeneration.
Measurement variability is not neuronal recovery.
And an apparent increase in RNFL thickness should never automatically be interpreted as restoration of retinal ganglion cells.
If regeneration is proposed, the evidentiary threshold must be substantially higher.
Structural findings would need to be reproducible, longitudinal and ideally accompanied by functional and biological correlates.
This distinction is essential because the possibility of neuronal restoration is now being actively reconsidered experimentally.
Research demonstrating axonal regeneration and restoration of visual function in animal models has challenged the traditional assumption that adult retinal ganglion cell damage is invariably irreversible.
That does not establish regeneration in human glaucoma.
But it changes the scientific question from:
“Is regeneration impossible?”
to:
“Under what biological conditions might restoration become possible?”
Prevention May Begin Before Neuroprotection
There is another consequence of this thinking.
Perhaps the most effective neuroprotection occurs before a neuron requires rescue.
If mitochondrial reserve declines gradually with ageing, metabolic disease, oxidative burden, vascular dysfunction and chronic cellular stress, then maintaining systemic health may indirectly influence neuronal resilience long before glaucoma becomes clinically advanced.
This brings ophthalmology into a much broader medical context.
Sleep.
Movement.
Metabolic health.
Blood pressure regulation.
Nutritional adequacy.
Avoidance of smoking.
Management of diabetes and vascular risk.
Circadian stability.
These should not be presented as proven treatments capable of stopping glaucoma.
But they influence biological systems upon which neuronal survival depends.
The distinction is subtle but important.
A healthy lifestyle is not a substitute for glaucoma treatment.
It may, however, contribute to the biological environment in which glaucoma treatment must succeed.
From Standard Therapy to Precision Neuroprotection
The future may therefore not lie in finding one universal “neuroprotective drug.”
It may lie in identifying different forms of vulnerability.
One patient may predominantly require aggressive pressure reduction.
Another may have pronounced vascular dysregulation.
Another may demonstrate metabolic vulnerability.
Another may combine several of these factors.
This suggests a transition from a uniform pressure-centred model toward precision neuroprotection.
Not every patient needs every intervention.
But every patient deserves the question:
What is driving progression in this particular eye?
Such an approach would combine established ophthalmological treatment with increasingly precise structural monitoring and, where indicated, investigation of systemic and metabolic contributors.
The purpose is not to medicalise every aspect of life.
It is to recognise that the retinal ganglion cell is part of a living human organism.
A Proposed Therapeutic Framework
The therapeutic strategy emerging from this VISION PAPER™ can therefore be summarised in five steps:
1. Detect neuronal damage early.
Do not wait for elevated pressure to initiate the search for glaucoma.
2. Reduce modifiable mechanical stress.
Lower intraocular pressure according to established evidence and individual risk.
3. Restore and maintain ocular homeostasis.
Consider the biological effects of interventions such as SLT in addition to their measurable pressure response.
4. Identify systemic and metabolic vulnerability.
When progression is not adequately explained by pressure, investigate factors capable of compromising perfusion, energy metabolism and neuronal resilience.
5. Explore neuroprotective strategies while maintaining scientific discipline.
Use emerging biological knowledge to generate and test interventions — while clearly distinguishing established therapy from translational hypotheses.
This is not a rejection of conventional glaucoma treatment.
It is its extension.
For decades, ophthalmology has become increasingly sophisticated in lowering intraocular pressure.
The next stage may require the same sophistication in understanding the patient whose optic nerve continues to deteriorate despite it.
Toward a Dynamic Treatment Model
The future of glaucoma therapy may therefore require a dynamic rather than a static treatment model:
Detect structural change early.
Intervene before irreversible loss.
Follow the neuronal response.
And intervene again when renewed vulnerability becomes visible.
This is the principle we propose as:
OCT-Guided Biological Intervention
6.5 Perfusion, Metabolism and the Whole Patient
Glaucoma occurs in the eye.
But the retinal ganglion cell lives within the biology of the whole patient.
This distinction becomes particularly important in normal-tension glaucoma.
When intraocular pressure is not markedly elevated, factors outside the traditional pressure model deserve greater attention. Ocular perfusion, vascular autoregulation, systemic blood pressure, metabolic health, sleep and cellular energy availability may all influence the environment in which the optic nerve must survive.
The Optic Nerve Depends on More Than Pressure
Adequate neuronal function requires a continuous supply of oxygen and metabolic substrates.
This supply depends not simply on blood pressure, but on the ability of the microcirculation to adapt to changing demand.
A patient may have apparently normal cardiovascular measurements during the day while experiencing substantial nocturnal blood pressure reductions, disturbed vascular regulation or periods of reduced ocular perfusion.
Particularly in normal-tension glaucoma, such patterns may matter.
The therapeutic question should therefore not always be:
How much lower can we make the intraocular pressure?
It may also be:
Is the optic nerve receiving what it needs to maintain cellular function?
Metabolism Connects the Eye to the Body
Mitochondrial function does not exist independently of systemic metabolism.
Glucose regulation, insulin sensitivity, micronutrient availability, vascular health, inflammatory signalling, oxidative burden and homocysteine metabolism are among the systemic factors capable of interacting with cellular energy production and vascular function.
Their precise contribution to glaucoma progression differs in strength of evidence and should not be overstated.
But the biological principle is difficult to ignore:
The retina cannot be metabolically separated from the organism that supplies it.
This has consequences for clinical thinking.
When structural deterioration continues despite apparently adequate pressure management, looking beyond the eye should not be regarded as abandoning ophthalmology.
It may represent a more complete form of ophthalmology.
Sleep, Circadian Biology and Recovery
Sleep deserves particular attention.
It influences autonomic regulation, blood pressure patterns, glucose metabolism, mitochondrial function, inflammatory signalling and cellular repair.
At the same time, nighttime physiology creates a unique situation for the optic nerve: systemic blood pressure may fall while intraocular pressure can change in the opposite direction.
This interaction may be especially relevant in vulnerable individuals.
Again, this does not make sleep therapy a treatment for glaucoma.
But it illustrates why the biological environment of the optic nerve cannot be understood from a daytime IOP measurement alone.
From the Eye to the Individual
A more integrated approach therefore does not require abandoning established glaucoma algorithms.
It requires adding another layer of questions.
What is the patient’s vascular situation?
What happens at night?
Is there evidence of metabolic vulnerability?
Are potentially modifiable systemic factors present?
And does the longitudinal OCT trajectory change when these factors and ocular treatment are addressed together?
The purpose is not to transform glaucoma into a vaguely defined systemic disease.
It is to recognise that neuronal survival is a systemic biological achievement.
The eye may reveal the damage.
But the conditions determining resilience may extend far beyond it.
And this leads to a final perspective.
If modern molecular medicine increasingly describes health in terms of homeostasis, resilience, adaptation and the capacity to recover from stress, it is worth asking whether these concepts are entirely new.
Or whether other medical traditions have been describing aspects of the same fundamental biological principle in a different language for centuries.
This is where Ayurveda offers an interesting perspective — not as a substitute for molecular science, but as another way of thinking about regulation, individual vulnerability and the preservation of balance.
6.6 A Different Language for Resilience: What Ayurveda May Add to the Question
Modern glaucoma research is increasingly moving toward concepts such as cellular resilience, metabolic reserve, mitochondrial function, vascular regulation and the capacity of neurons to adapt to stress.
These concepts belong to modern molecular medicine.
Yet the underlying idea — that health depends not only on the absence of a damaging factor, but on the organism’s ability to maintain and restore balance — is much older.
Ayurveda offers an interesting perspective in this context.
Not because Ayurvedic concepts can be equated with mitochondrial biology, retinal ganglion cell metabolism or modern neurophysiology.
They cannot.
And not because traditional medicine should replace evidence-based glaucoma treatment.
It should not.
The value lies elsewhere.
A Different Way of Describing Vulnerability
Ayurvedic medicine views health as a dynamic state of regulation rather than simply the absence of disease.
Individual constitution, environmental influences, nutrition, sleep, stress, ageing and daily rhythms are considered part of a continuously changing biological balance.
Disease is therefore not understood exclusively as an isolated defect in one organ.
It may emerge when the organism progressively loses its ability to compensate for internal and external disturbance.
The terminology is different from that of molecular medicine.
But the question is surprisingly familiar:
Why does one individual remain stable under a particular stress while another becomes vulnerable?
Modern glaucoma research asks essentially the same question when two patients with similar intraocular pressure develop completely different trajectories of retinal ganglion cell loss.
Vata, Pitta and Kapha Are Not Molecular Pathways
Scientific discipline requires a clear boundary.
The Ayurvedic concepts of Vata, Pitta and Kapha should not be translated directly into neurotransmitters, mitochondrial pathways, inflammatory mediators or vascular mechanisms.
Such one-to-one comparisons would oversimplify both systems.
They are different explanatory frameworks developed in different historical and scientific contexts.
But Ayurveda contributes something that modern highly specialised medicine can sometimes lose:
attention to patterns.
Sleep and wakefulness.
Activity and recovery.
Nutrition and digestion.
Stress and adaptation.
Environment and season.
Individual constitution and individual response.
Rather than asking only which isolated parameter is abnormal, Ayurveda traditionally asks whether the organism as a whole remains capable of maintaining equilibrium.
This does not provide a molecular explanation for glaucoma.
But it may encourage a clinically valuable question:
What is reducing this patient’s capacity to compensate?
From Balance to Homeostasis
Modern physiology uses a different vocabulary.
We speak of homeostasis.
Allostasis.
Autonomic regulation.
Circadian biology.
Mitochondrial reserve.
Metabolic flexibility.
Oxidative balance.
Vascular autoregulation.
Cellular stress responses.
These concepts are measurable and increasingly mechanistically defined.
Yet they share a broad principle:
Biological systems survive by continuously adapting to change.
A healthy system is not static.
It is capable of being disturbed and returning toward equilibrium.
This may also be relevant to the retinal ganglion cell.
The therapeutic goal may therefore not simply be to remove every possible stressor.
That is impossible.
It may be to reduce excessive stress while preserving or strengthening the biological capacity to respond to it.
East and West Should Not Compete
The future of medicine does not require choosing between traditional and modern thinking.
It requires knowing what each can — and cannot — contribute.
Modern science provides measurement, mechanism, controlled experimentation and the ability to test causality.
Traditional medical systems may contribute long-developed observations about individual variability, rhythms, behaviour, environment and the relationship between different aspects of health.
One should not be used to validate the other without evidence.
But different perspectives can generate new questions.
And new questions are precisely where scientific discovery begins.
Perhaps the most productive relationship between Eastern and Western medicine is therefore not one of equivalence.
It is one of intellectual dialogue.
A traditional concept may inspire a hypothesis.
Modern science must then determine whether that hypothesis survives measurement and experimentation.
This principle is entirely consistent with the purpose of the VISION PAPER™:
to connect observations and disciplines without confusing hypothesis with proof.
⸻
Conclusion — From Lowering Pressure to Preserving the Neuron
Glaucoma treatment has achieved something remarkable.
We can measure intraocular pressure precisely.
We can lower it pharmacologically, with laser treatment and surgically.
And doing so protects vision.
None of this should be diminished.
But normal-tension glaucoma confronts us with an uncomfortable fact:
Retinal ganglion cells can degenerate even when intraocular pressure was never conventionally elevated.
This means that pressure is critically important — but it cannot be the entire biological explanation.
VISION PAPER™ No. 6 therefore proposes an expanded therapeutic perspective.
The first principle remains established:
reduce modifiable mechanical stress.
But beyond pressure, we should investigate the biological conditions that determine neuronal vulnerability.
SLT provides an intriguing example.
What began as a pressure-lowering laser procedure is increasingly understood to initiate biological processes involving monocytes and macrophages, cytokine signalling, extracellular matrix remodelling and trabecular cellular behaviour.
Our long-term clinical observations raise the further hypothesis that its therapeutic relevance may not always be fully represented by the magnitude of pressure reduction alone.
The same expansion of thinking applies to the retinal ganglion cell itself.
Mitochondrial function, NAD⁺ metabolism, ATP availability, oxidative stress, vascular supply and cellular stress responses are increasingly becoming part of the scientific discussion surrounding glaucoma neurodegeneration.
This leads from pressure reduction toward metabolic neuroprotection.
And clinical observation adds another dimension.
In longitudinal OCT follow-up, we have observed structural trajectories in which RNFL decline was followed by stabilization or an increase in measured RNFL thickness after SLT combined with resveratrol-based metabolic support. In some patients, renewed structural decline was followed by repeated intervention and subsequently by another measured increase.
These observations do not prove retinal ganglion cell regeneration.
They do not establish causality.
But their repetition creates a hypothesis that should be tested rather than ignored.
From these observations we propose the concept of:
OCT-Guided Biological Intervention
A dynamic model in which OCT is not used merely to document damage after it has occurred, but to follow neuronal structure longitudinally, identify renewed vulnerability, guide reassessment and intervention, and subsequently observe the structural response.
The sequence becomes:
Detect → Intervene → Observe → Reassess → Intervene Again When Necessary.
This is not yet an established therapeutic algorithm.
It is a proposal for investigation.
And that distinction represents the central philosophy of the VISION PAPER™ itself.
Science requires evidence.
But before evidence exists, someone must be permitted to observe.
Someone must connect findings that have previously remained separate.
And someone must formulate the question.
Clinical observations in humans should not be considered irrelevant simply because experimental mechanisms are still being investigated in animals or because prospective trials have not yet been completed.
Nor should experimental findings be translated prematurely into clinical claims.
The two must meet.
The future of glaucoma therapy may therefore not be defined by one new drug, one new laser or one new biomarker.
It may emerge from a change in perspective:
from pressure to vulnerability,
from damage to resilience,
from static diagnosis to longitudinal biological observation,
and from treating an isolated eye to understanding the biology of the individual in whom that eye exists.
Eastern and Western medicine may describe aspects of resilience in very different languages.
Modern science must determine which mechanisms are real, measurable and therapeutically relevant.
But both perspectives remind us of something fundamental:
Survival is not simply the absence of stress.
It is the capacity to respond to it.
And perhaps that is the deeper therapeutic question in glaucoma:
Not only how do we lower the pressure — but how do we help the neuron survive?
17.08.2026
Copyright
© 2026 Sylvia Paulig. All rights reserved.
